-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
To find non-invasing biomarkers for early diagnosis of stomach cancer (GC), a research paper was published recently in British Journal of Cancer, an authoritative journal in the field of oncology.
a case-control study using urine samples from early GC and healthy controlled (HC) patients.
372 GC patients and 282 HCs of age matching gender were randomly divided into three groups: 18 patients found in the queue; 176 patients in the training queue and 88 patients in the validation queue.
a comprehensive quantitative proteomic analysis of urine proteins, in addition to helicobacter pyridobacteria status, the levels of TFF1 (uTFF1) and ADAM12 (uADAM12) in urine are important independent diagnostic markers of GC.
in the training and validation queue, the urine biomarker groups of uTFF1, uADAM12 and Helicobacter pyridosis were combined to distinguish HC and GC patients significantly.
analysis of gender-specific biomarkers, the combined group had an AUC of 0.858 for male GC diagnoses, while a combination of uTFF1, uBARD1 and Helicobacter pyridosis had 0.893 for female GC diagnoses.
note that each combination can even distinguish between I-period GC patients and HC patients (male AAUC=0.850; female AAUC=0.845).
, it can be seen that the new urine protein biomarkers are promising GC noninvasional biomarkers, including early diseases.
.
